SOST and osteoporosis: The change in osteoblasts to BLCs was thought to result from the inhibition of Wnt signaling by sclerostin from osteocytes.(6) Romosozumab, an antisclerostin antibody used for the treatment of osteoporosis, is thought to activate BLCs and contribute to bone formation.